Developments in laboratory automation, personalized medicine, point-of-care testing, and patient self-testing are driving significant growth in the molecular diagnostics market. However, tighter FDA regulations and requirements for additional safety and effectiveness data mean potentially longer and more costly clinical validation studies that can delay time to market.
GBC recognizes that today's diagnostics innovators face these time-critical and budget-sensitive challenges. For this reason it is increasingly important for companies to seek out the best industry expertise and value to address these critical business needs. With more than 20 years of clinical research and biospecimen management experience, GBC seeks to meet these needs and help clients execute trials of improved efficiency supporting product development and approval.
Neil R. Mucci, CEO and Founder at Global BioClinical (GBC)